Hypofractionated radiotherapy combined with bevacizumab plus low-dose ifosfamide, carboplatin, and etoposide as second-line chemoradiotherapy for progressing spinal diffuse midline glioma, H3K27-altered: illustrative case
Spinal DMG is a malignant tumor with a poor prognosis. However, treatment with additional HFRT combined with BEV plus low-dose ICE may inhibit tumor progression to prolong the progression-free period and survival. https://thejns.org/doi/10.3171/CASE2464.
Authors
- Shintaro Nakayasu
- Megumi Uto
- Takashi Mizowaki (ORCID: https://orcid.org/0000-0002-8135-8746)
- Masahiro Tanji (ORCID: https://orcid.org/0009-0002-2459-1856)
- Etsuko Hattori (ORCID: https://orcid.org/0000-0002-2975-774X)
- Yasuhide Takeuchi (ORCID: https://orcid.org/0000-0002-1262-2355)
- Yukinori Terada (ORCID: https://orcid.org/0000-0002-1357-6178)
- Yoshiki Arakawa (ORCID: https://orcid.org/0000-0003-4626-4645)
- Noritaka Sano (ORCID: https://orcid.org/0000-0002-8999-1976)
- Yasuhide Makino
- Yohei Mineharu
Institutions
- Kyoto University (JP)
- Kyoto University Hospital (JP)
Publication Details
- Journal
- Journal of Neurosurgery Case Lessons
- Published
- 2024-08-12
- DOI
- https://doi.org/10.3171/case2464
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Stryker
- Taiho Pharmaceutical
- Novocure
- Nihon Medi-Physics
- Incyte
- Eisai
- Astellas Pharma
- Servier
- Ono Pharmaceutical
- Chugai Pharmaceutical
- Daiichi Sankyo Europe